Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction

Journal of the American College of Cardiology

Volumn 29, Issue 5, 1997, Pages 908-912

  Zijlstra, Felix ^a   Beukema, Willem P ^a   Van'T Hof, Arnoud W J ^a   Liem, Aylee ^a   Reiffers, Stoffer ^a   Hoorntje, Jan C A ^a   Suryapranata, Harry ^a   De Boer, Menko Jan ^a  

^a HOSPITAL DE WEEZENLANDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK ASSESSMENT; STREPTOKINASE; STROKE VOLUME; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0030935881     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00018-1     Document Type: Article

References (36)

1. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 328:1993;673-679.
2. de Boer MJ, Suryapranata H, Hoorntje JCA, et al. Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction. Circulation. 90:1994;753-761.
3. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 328:1993;680-684.
4. de Boer MJ, Reiber JHC, Suryapranata H, van den Brand MJBM, Hoorntje JCA, Zijlstra F. Angiographic findings and catheterisation laboratory events in patients with primary coronary angioplasty or streptokinase therapy for acute myocardial infarction. Eur Heart J. 16:1995;1347-1355.
5. Kligfield P. Primary angioplasty in myocardial infarction. Br Heart J. 73:1995;403.
6. Zijlstra F. Primary Angioplasty the most effective therapy for patients with an acute myocardial infarction . Br Heart J. 73:1995;403-404.
7. Grines CL, O'Neill WW. Primary angioplasty. Br Heart J. 73:1995;405-406.
8. De Jaegere PP, Simoons ML. Immediate angioplasty a conservative view from Europe . Br Heart J. 73:1995;407-408.
9. Vaitkus PT. Limitations of primary angioplasty in acute myocardial infarction. Br Heart J. 73:1995;409-410.
10. Brodie BR. Primary angioplasty in a community hospital in the USA. Br Heart J. 73:1995;411-412.
11. Boyle RM. Immediate angioplasty in the United Kingdom. Br Heart J. 73:1995;413-414.
12. Ramsdale DR, Grech ED. Experience of primary angioplasty in the United Kingdom. Br Heart J. 73:1995;414-416.
13. de Boer MJ, Hoorntje JCA, Ottervanger JP, Reiffers S, Suryapranata H, Zijlstra F. Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction left ventricular ejection fraction, hospital mortality and reinfarction . J Am Coll Cardiol. 23:1994;1004-1008.
14. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med. 115:1991;173-177.
15. Hillis LD, Forman S, Braunwald E, et al. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 16:1990;313-315.
16. Brodie BR, Weintraub RA, Stuckey TD, et al. Outcomes of direct coronary angioplasty for acute myocardial infarction in candidates and non-candidates for thrombolytic therapy. Am J Cardiol. 67:1991;7-12.
17. Simoons ML, Arnold AER. Tailored thrombolytic therapy a perspective . Circulation. 88:1993;2556-2564.
18. Gill JB, Cairns JA, Roberts RS. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med. 334:1996;65-70.
19. Meijer A, Verheugt FWA, Werter CJPJ, Lie KI, van der Pol JMJ, van Eenige MJ. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis a prospective placebo-controlled angiographic study: results of the APRICOT study . Circulation. 87:1993;1524-1530.
20. White HD, French JK, Hamer AW, et al. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year effects of antiplatelet therapy . J Am Coll Cardiol. 25:1995;218-223.
21. Barbagelata A, Granger CB, Topol EJ, et al. Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. Am J Cardiol. 76:1995;1007-1013.
22. Lieu TA, Gurley J, Lundstrom RJ, Parmley WW. Primary angioplasty and thrombolysis for acute myocardial infarction an evidence summary . J Am Coll Cardiol. 27:1996;737-750.
23. de Boer MJ, van Hout BA, Liem AL, Suryapranata H, Hoorntje JCA, Zijlstra F. A cost-effective analysis of primary angioplasty versus thrombolysis for acute myocardial infarction. Am J Cardiol. 76:1995;830-833.
24. Zijlstra F, de Boer MJ, Beukema WP, et al. Mortality, reinfarction, left ventricular ejection fraction and costs following reperfusion therapies for acute myocardial infarction. Eur Heart J. 17:1996;382-387.
25. van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and C/E ratios alongside a clinical trial. Health Econ. 3:1994;309-319.
26. Zijlstra F, Beukema WP, Liem AL, Suryapranata H, Hoorntje JCA, de Boer MJ. Results of the pilot phase of an ongoing randomized trial to evaluate a strategy of primary angioplasty for high risk and thrombolysis for low risk patients with acute myocardial infarction [abstract]. Circulation. 90:(Suppl I):1994;I-168.
27. Brodie B, Grines CL, Spain M, et al. A prospective, randomised trial evaluating early discharge (day 3) without non-invasive risk stratification in low risk patients with acute myocardial infarction PAMI-2 [abstract] . J Am Coll Cardiol. 25:1995;5A.
28. Mueller HS, Forman SA, Menegus MA, Cohen LS, Knatterud GL, Braunwald E. Prognostic significance of nonfatal reinfarction during 3-year follow-up results of the thrombolysis in myocardial infarction (TIMI) phase 2 clinical trial . J Am Coll Cardiol. 26:1995;900-907.
29. The effect of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615-1622.
30. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
31. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 332:1995;1418-1424.
32. Arnold AER, Simoons ML. Thrombolytic therapy for evolving myocardial infarction needs an approach that integrates benefit and risk. Eur Heart J. 16:1995;1502-1509.
33. Volpi A, DeVita C, Franzosi MG, et al. Predictors of nonfatal reinfarction in survivors of myocardial infarction after thrombolysis results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) Data Base . J Am Coll Cardiol. 24:1994;608-615.
34. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis Mortality and functional outcomes in the Gusto-I trial . Circulation. 92:1995;2811-2818.
35. Brodie BR, Grines CL, Ivanhoe R, et al. Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Circulation. 25:1994;156-162.
36. Grande P, Kyst Madsen J, Saunamäki K, et al. The Danish multicentre randomized study of invasive versus conservative treatment in patients with inducible ischaemia following thrombolysis in acute myocardial infarction (DANAMI) [abstract]. Eur Heart J. 17:(Suppl A):1996;559.